Molecular Mechanisms: Connections between Nonalcoholic Fatty Liver Disease, Steatohepatitis and Hepatocellular Carcinoma
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
Nonalcoholic fatty liver disease (NAFLD), including nonalcoholic steatohepatitis (NASH), causes hepatic fibrosis, cirrhosis and hepatocellular carcinoma (HCC). The patatin-like phospholipase-3 (PNPLA3) I148M sequence variant is one of the strongest genetic determinants of NAFLD/NASH. PNPLA3 is an independent risk factor for HCC among patients with NASH. The obesity epidemic is closely associated with the rising prevalence and severity of NAFLD/NASH. Furthermore, metabolic syndrome exacerbates the course of NAFLD/NASH. These factors are able to induce apoptosis and activate immune and inflammatory pathways, resulting in the development of hepatic fibrosis and NASH, leading to progression toward HCC. Small intestinal bacterial overgrowth (SIBO), destruction of the intestinal mucosa barrier function and a high-fat diet all seem to exacerbate the development of hepatic fibrosis and NASH, leading to HCC in patients with NAFLD/NASH. Thus, the intestinal microbiota may play a role in the development of NAFLD/NASH. In this review, we describe recent advances in our knowledge of the molecular mechanisms contributing to the development of hepatic fibrosis and HCC in patients with NAFLD/NASH.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239
EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836
Nonalcoholic Steatohepatitis: A Proposal for Grading and Staging The Histological Lesions
Brunt, E. M., Janney, C. G., Di Bisceglie, A. M., Neuschwander-Tetri, B. A., & Bacon, B. R. (1999) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.1999.01377.x · Cited by 3,907 · cited 4×
“The concept of NASH was first established in the context of pathology studies of the liver [5,6].”
BackgroundInfluentialGenetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease
Romeo, S., Kozlitina, J., Xing, C., Pertsemlidis, A., Cox, D., Pennacchio, L. A., Boerwinkle, E., Cohen, J. C., & Hobbs, H. H. (2008) · Nature Genetics · doi:10.1038/ng.257 · Cited by 3,416
Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.
MATTEONI, C., YOUNOSSI, Z., GRAMLICH, T., BOPARAI, N., LIU, Y., & MCCULLOUGH, A. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70506-8 · Cited by 3,345 · cited 2×
“also found that Matteoni type 4 NAFLD is both a genetically and clinically different subset from the other spectra of the disease and that the PNPLA3 variant is strongly associated with the progression of NASH in Japanese patients with NAFLD [89,90].”
BackgroundResultLudwig, J., Viggiano, T. R., McGill, D. B., & Ott, B. J. (1980) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(24)00530-5 · Cited by 2,903
The Natural History of Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study
Adams, L. A., Lymp, J. F., St. Sauver, J., Sanderson, S. O., Lindor, K. D., Feldstein, A., & Angulo, P. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.04.014 · Cited by 2,890
Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity
Henao-Mejia, J., Elinav, E., Jin, C., Hao, L., Mehal, W. Z., Strowig, T., Thaiss, C. A., Kau, A. L., Eisenbarth, S. C., Jurczak, M. J., et al. (2012) · Nature · doi:10.1038/nature10809 · Cited by 2,435 · cited 5×
“observed that the increased severity of NASH in Asc- and Il18-deficient mice is transmissible to cohoused wild-type mice [16].”
BackgroundResultInfluentialInflammatory links between obesity and metabolic disease
Lumeng, C. N., & Saltiel, A. R. (2011) · Journal of Clinical Investigation · doi:10.1172/jci57132 · Cited by 2,319 · cited 1×
“M1-skewed inflammation accompanies diet-induced obesity in the liver and adipose tissue [28].”
BackgroundMolecular mediators of hepatic steatosis and liver injury
Browning, J. D., & Horton, J. D. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200422422 · Cited by 1,772 · cited 1×
“Thus, the progression of NAFLD to cirrhosis and HCC may differ in different ethnic groups [84].”
BackgroundIncreased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease
Miele, L., Valenza, V., La Torre, G., Montalto, M., Cammarota, G., Ricci, R., Mascianà, R., Forgione, A., Gabrieli, M. L., Perotti, G., et al. (2009) · Hepatology · doi:10.1002/hep.22848 · Cited by 1,434 · cited 1×
“In one experiment, the intestinal mucosa barrier function was shown to have changed, resulting in the progression of nonalcoholic steatohepatitis in rats [15].”
BackgroundFrom NASH to HCC: current concepts and future challenges
Anstee, Q. M., Reeves, H. L., Kotsiliti, E., Govaere, O., & Heikenwalder, M. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0145-7 · Cited by 1,392 · cited 1×
“In NAFLD/NASH-associated HCC, including its epidemiology, the key feature is the hepatic NAFLD/NASH microenvironment that promotes hepatocarcinogenesis [115].”
BackgroundThe role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
Kazankov, K., Jørgensen, S. M. D., Thomsen, K. L., Møller, H. J., Vilstrup, H., George, J., Schuppan, D., & Grønbæk, H. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0082-x · Cited by 941
A Protein-Truncating HSD17B13 Variant and Protection from Chronic Liver Disease
Abul-Husn, N. S., Cheng, X., Li, A. H., Xin, Y., Schurmann, C., Stevis, P., Liu, Y., Kozlitina, J., Stender, S., Wood, G. C., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1712191 · Cited by 827 · cited 4×
“A meta-analysis of four randomized trials involving 134 NAFLD and NASH patients revealed that probiotic therapies can reduce AST, ALT, total cholesterol and TNF-α, and improve insulin resistance in these patients [52].”
BackgroundInfluentialYounossi, Z. M., Otgonsuren, M., Henry, L., Venkatesan, C., Mishra, A., Erario, M., & Hunt, S. (2015) · Hepatology · doi:10.1002/hep.28123 · Cited by 802
Intestinal microbiota in patients with nonalcoholic fatty liver disease
Mouzaki, M., Comelli, E. M., Arendt, B. M., Bonengel, J., Fung, S. K., Fischer, S. E., McGilvray, I. D., & Allard, J. P. (2013) · Hepatology · doi:10.1002/hep.26319 · Cited by 749 · cited 3×
“Patients with NASH were shown to have a lower percentage of Bacteroidetes (Bacteroidetes to total bacteria counts) than those with simple steatosis or living liver donors (representing healthy controls) [49].”
BackgroundInfluentialMouries, J., Brescia, P., Silvestri, A., Spadoni, I., Sorribas, M., Wiest, R., Mileti, E., Galbiati, M., Invernizzi, P., Adorini, L., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.08.005 · Cited by 688
Mittal, S., El-Serag, H. B., Sada, Y. H., Kanwal, F., Duan, Z., Temple, S., May, S. B., Kramer, J. R., Richardson, P. A., & Davila, J. A. (2016) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2015.07.019 · Cited by 648 · cited 2×
“Having NAFLD or metabolic syndrome was independently associated with HCC in the absence of cirrhosis [73].”
BackgroundHepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team
Dyson, J., Jaques, B., Chattopadyhay, D., Lochan, R., Graham, J., Das, D., Aslam, T., Patanwala, I., Gaggar, S., Cole, M., et al. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2013.08.011 · Cited by 603
Liu, Y.-L., Patman, G. L., Leathart, J. B. S., Piguet, A.-C., Burt, A. D., Dufour, J.-F., Day, C. P., Daly, A. K., Reeves, H. L., & Anstee, Q. M. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.02.030 · Cited by 549 · cited 1×
“444C>G minor allele (encoding the I148M variant) was associated not only with a greater risk of progressive steatohepatitis and fibrosis but also with HCC in patients with NAFLD [92].”
BackgroundZhou, D., Pan, Q., Shen, F., Cao, H.-X., Ding, W.-J., Chen, Y.-W., & Fan, J.-G. (2017) · Scientific Reports · doi:10.1038/s41598-017-01751-y · Cited by 421
Bile Acids and Dysbiosis in Non-Alcoholic Fatty Liver Disease
Mouzaki, M., Wang, A. Y., Bandsma, R., Comelli, E. M., Arendt, B. M., Zhang, L., Fung, S., Fischer, S. E., McGilvray, I. G., & Allard, J. P. (2016) · PLOS ONE · doi:10.1371/journal.pone.0151829 · Cited by 385 · cited 1×
“In adult patients with NAFLD, dysbiosis is associated with altered bile acid homeostasis, which renders patients at increased risk of hepatic injury [55].”
BackgroundAssociation of histologic disease activity with progression of nonalcoholic fatty liver disease
Kleiner, D. E., Brunt, E. M., Wilson, L. A., Behling, C., Guy, C., Contos, M., Cummings, O., Yeh, M., Gill, R., Chalasani, N., et al. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.12565 · Cited by 372
Effects of probiotics on nonalcoholic fatty liver disease: A meta-analysis
Ma, Y.-Y. (2013) · World Journal of Gastroenterology · doi:10.3748/wjg.v19.i40.6911 · Cited by 352
ER Stress Drives Lipogenesis and Steatohepatitis via Caspase-2 Activation of S1P
Kim, J. Y., Garcia-Carbonell, R., Yamachika, S., Zhao, P., Dhar, D., Loomba, R., Kaufman, R. J., Saltiel, A. R., & Karin, M. (2018) · Cell · doi:10.1016/j.cell.2018.08.020 · Cited by 333 · cited 2×
“ER stress can drive lipogenesis and steatohepatitis via caspase-2 activation of site 1 protease [24].”
BackgroundAlexander, M., Loomis, A. K., van der Lei, J., Duarte-Salles, T., Prieto-Alhambra, D., Ansell, D., Pasqua, A., Lapi, F., Rijnbeek, P., Mosseveld, M., et al. (2019) · BMC Medicine · doi:10.1186/s12916-019-1321-x · Cited by 317 · cited 1×
“A recent real-world study of 18 million patients in four European cohorts demonstrated that the strongest independent predictor of a diagnosis of HCC or cirrhosis was a baseline diagnosis of diabetes [113].”
BackgroundSchwimmer, J. B., Johnson, J. S., Angeles, J. E., Behling, C., Belt, P. H., Borecki, I., Bross, C., Durelle, J., Goyal, N. P., Hamilton, G., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.06.028 · Cited by 298
Da Silva, H. E., Teterina, A., Comelli, E. M., Taibi, A., Arendt, B. M., Fischer, S. E., Lou, W., & Allard, J. P. (2018) · Scientific Reports · doi:10.1038/s41598-018-19753-9 · Cited by 283
Dysregulated hepatic bile acids collaboratively promote liver carcinogenesis
Xie, G., Wang, X., Huang, F., Zhao, A., Chen, W., Yan, J., Zhang, Y., Lei, S., Ge, K., Zheng, X., et al. (2016) · International Journal of Cancer · doi:10.1002/ijc.30219 · Cited by 252
Oxidative stress promotes pathologic polyploidization in nonalcoholic fatty liver disease
Gentric, G., Maillet, V., Paradis, V., Couton, D., L’Hermitte, A., Panasyuk, G., Fromenty, B., Celton-Morizur, S., & Desdouets, C. (2015) · Journal of Clinical Investigation · doi:10.1172/jci73957 · Cited by 240 · cited 1×
“Oxidative stress also promotes pathological polyploidization, which is an early event in NAFLD and may contribute to HCC development [110].”
BackgroundCYP2E1 potentiates binge alcohol-induced gut leakiness, steatohepatitis, and apoptosis
Abdelmegeed, M. A., Banerjee, A., Jang, S., Yoo, S.-H., Yun, J.-W., Gonzalez, F. J., Keshavarzian, A., & Song, B.-J. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.09.009 · Cited by 191
Mechanisms of Insulin Resistance in Primary and Secondary Nonalcoholic Fatty Liver
Jelenik, T., Kaul, K., Séquaris, G., Flögel, U., Phielix, E., Kotzka, J., Knebel, B., Fahlbusch, P., Hörbelt, T., Lehr, S., et al. (2017) · Diabetes · doi:10.2337/db16-1147 · Cited by 154 · cited 1×
“The hyperinsulinemia induced by peripheral insulin resistance can stimulate lipogenesis in the liver [21].”
BackgroundGarcía‐Lezana, T., Raurell, I., Bravo, M., Torres‐Arauz, M., Salcedo, M. T., Santiago, A., Schoenenberger, A., Manichanh, C., Genescà, J., Martell, M., et al. (2018) · Hepatology · doi:10.1002/hep.29646 · Cited by 136
Cited by
Mechanisms and disease consequences of nonalcoholic fatty liver disease
Loomba, R., Friedman, S. L., & Shulman, G. I. (2021) · Cell · doi:10.1016/j.cell.2021.04.015 · Cited by 2,002
“As discussed above, the gut microbiome is increasingly implicated in NASH pathogenesis, and more recent observations extend its role to the pathogenesis of HCC (Chu et al., 2018a; Henao-Mejia et al., 2012; Kanda et al., 2020; Sydor et al., 2020).”
BackgroundLeFort, K. R., Rungratanawanich, W., & Song, B.-J. (2024) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-023-05061-7 · Cited by 202
“Gut dysbiosis is responsible for the exacerbation and progression of various liver diseases [386] through the promotion of toxic metabolites [150]; in fact, targeting gut dysbiosis has the potential to mitigate the onset and progression of liver diseases [150, 387].”
BackgroundDiabetes medications and risk of HCC
Plaz Torres, M. C., Jaffe, A., Perry, R., Marabotto, E., Strazzabosco, M., & Giannini, E. G. (2022) · Hepatology · doi:10.1002/hep.32439 · Cited by 86
Metadata
- Authors
- Kanda, T., Goto, T., Hirotsu, Y., Masuzaki, R., Moriyama, M., & Omata, M.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2020-02-23
- Volume
- 21
- Issue
- 4
- Pages
- 1525
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W3007282770
- Cited by
- 94
- References
- 34
- FWCI
- 11.06
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.